Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVN001 in Subjects With Dry Eye Disease
NCT04556838Phase 2Completed
- Sponsor
- VivaVision Biotech
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VVN001 in dry eye disease (DED) (3 arms), sponsored by VivaVision Biotech. Primary endpoint: Inferior Corneal Fluorescein Staining at Day 84. Started Dec 2020; status: completed.
02
Drugs
VVN001
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04556838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556838.